Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3 .

Mark J Levis Mehdi Hamadani Brent R LoganRichard J JonesAnurag K SinghMark R Litzow John R WingardEsperanza B PapadopoulosAlexander E Perl Robert J Soiffer Celalettin Ustun Masumi Ueda Oshima Geoffrey L Uy Edmund K WallerSumithra VasuMelham M Solh Asmita Mishra Lori S Muffly Hee-Je KimJan-Henrik MikeschYuho Najima Masahiro OnozawaKirsty ThomsonArnon Nagler Andrew H WeiGuido MarcucciNancy L GellerNahla HasabouDavid DelgadoMatt RosalesJason E Hill Stanley C GillRishita NuthethiDenise KingHeather WittsackAdam MendizabalSteven M Devine Mary M Horowitz Yi-Bin Chennull null

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT therapy.

Keyphrases

acute myeloid leukemia
healthcare
allogeneic hematopoietic stem cell transplantation
randomized controlled trial
systematic review
cell cycle arrest
electronic health record
big data
stem cells
machine learning
cell death
cell proliferation
mesenchymal stem cells
pi k akt